half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-11 and is reviewed periodically as new material appears.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估，而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
The normal form of ice on the surface of Earth is ice Ih, a phase that forms crystals with hexagonal symmetry. Another with cubic crystalline symmetry, ice Ic, can occur in the upper atmosphere. As the pressure increases, ice forms other crystal structures. As of 2024, twenty have been experimentally confirmed and several more are predicted theoretically. The eighteenth form of ice, ice XVIII, a face-centred-cubic, superionic ice phase, was discovered when a droplet of water was subject to a shock wave that raised the water's pressure to millions of atmospheres and its temperature to thousands of degrees, resulting in a structure of rigid oxygen atoms in which hydrogen atoms flowed freely. When sandwiched between layers of graphene, ice forms a square lattice. The details of the chemical nature of liquid water are not well understood; some theories suggest that its unusual behavior is due to the existence of two liquid states.
==== Lactic acid ==== It was once believed that lactic acid build-up was the cause of muscle fatigue. The assumption was lactic acid had a "pickling" effect on muscles, inhibiting their ability to contract. Though the impact of lactic acid on performance is now uncertain, it may assist or hinder muscle fatigue. Produced as a by-product of fermentation, lactic acid can increase intracellular acidity of muscles. This can lower the sensitivity of contractile apparatus to Ca2+ but also has the effect of increasing cytoplasmic Ca2+ concentration through an inhibition of the chemical pump that actively transports calcium out of the cell. This counters inhibiting effects of potassium on muscular action potentials. Lactic acid also has a negating effect on the chloride ions in the muscles, reducing their inhibition of contraction and leaving potassium ions as the only restricting influence on muscle contractions, though the effects of potassium are much less than if there were no lactic acid to remove the chloride ions. Ultimately, it is uncertain if lactic acid reduces fatigue through increased intracellular calcium or increases fatigue through reduced sensitivity of contractile proteins to Ca2+. Lactic acid is now used as a measure of endurance training effectiveness and VO2 max.
== Role of neurite-promoting factors == Neurite promoting factors include many extracellular matrix proteins produced by Schwann cells at the distal stump including fibronectin and laminin. Fibronectin are components of the basal lamina and promote neurite growth and adhesion of the growth cone to the basal lamina. In regenerating neural cells, neurite promoting factors play a role in adhesion of the axon and include neural cell adhesion molecule (N-CAM) and N-cadherin.
=== Gene silencing === The PCSK9 antisense oligonucleotide increases expression of the LDLR and decreases circulating total cholesterol levels in mice. A locked nucleic acid reduced PCSK9 mRNA levels in mice. Initial clinical trials showed positive results of ALN-PCS, which acts by means of RNA interference. In 2021, scientists demonstrated that CRISPR gene editing can decrease blood levels of LDL cholesterol in vivo in Macaca fascicularis monkeys for months by 60% via knockdown of PCSK9 in the liver. In 2023, a clinical trial demonstrated that VERVE-101 gene therapy, which works via CRISPR gene editing, could reduce LDL cholesterol by as much as 55% in human volunteers with heterozygous familial hypercholesterolemia.
Tens of genes and CNVs have been definitively identified based on the observation of recurrent mutations in different individuals, and suggestive evidence has been found for over 100 others. The Simons Foundation Autism Research Initiative (SFARI) details the evidence for each genetic locus associated with autism. These early gene and CNV findings have shown that the cognitive and behavioral features associated with each of the underlying mutations is variable. Each mutation is itself associated with a variety of clinical diagnoses, and can also be found in a small percentage of individuals with no clinical diagnosis. Thus the genetic disorders that comprise autism are not autism-specific. The mutations themselves are characterized by considerable variability in clinical outcome and typically only a subset of mutation carriers meet criteria for autism. This variable expressivity results in different individuals with the same mutation varying considerably in the severity of their observed particular trait. The conclusion of these recent studies of de novo mutation is that the spectrum of autism is breaking up into quanta of individual disorders defined by genetics. One gene that has been linked to autism is SHANK2. Mutations in this gene act in a dominant fashion and appear to cause hyperconnectivity between the neurons. A study conducted on 42,607 autism cases has identified 60 new genes, five of which had a more moderate impact on autistic symptoms. The related gene variants were often inherited from the participant's parents.
Sources: en.wikipedia.org
Open file backup: Many backup software applications undertake to back up open files in an internally consistent state. Some applications simply check whether open files are in use and try again later. Other applications exclude open files that are updated very frequently. Some low-availability interactive applications can be backed up via natural/induced pausing. Interrelated database files backup: Some interrelated database file systems offer a means to generate a "hot backup" of the database while it is online and usable. This may include a snapshot of the data files plus a snapshotted log of changes made while the backup is running. Upon a restore, the changes in the log files are applied to bring the copy of the database up to the point in time at which the initial backup ended. Other low-availability interactive applications can be backed up via coordinated snapshots. However, genuinely-high-availability interactive applications can be only be backed up via Continuous Data Protection.
Biden also faced significant opposition from uncommitted voters and the Uncommitted National Movement in their protest vote movement against Biden due to his support for Israel during the Gaza war, which collectively won 36 delegates. Following a "disastrous" June 2024 debate performance against Trump that "inflamed age concerns", Biden ultimately withdrew from the race on July 21, 2024, and immediately endorsed Kamala Harris to replace him in his place as the party's presidential nominee. Harris quickly announced her own presidential campaign later that day and by the next day, Harris had secured the non-binding support of enough uncommitted delegates that were previously pledged to Biden to make her the party's presumptive nominee. Biden's withdrawal made him the first eligible incumbent president since Lyndon B. Johnson in 1968 not to seek re-election, and the first to withdraw after securing enough delegates to win the nomination. Harris is the first presidential nominee who did not participate in the presidential primaries since Vice President Hubert Humphrey, also in 1968, and the first since the modern Democratic Party primary procedure was created in 1972 (prior to which most states did not hold primary elections). On August 5, 2024, after five days of online balloting, Democratic National Convention delegates voted to make Harris the party's 2024 presidential nominee. She selected Minnesota Governor Tim Walz as her running mate the following day and accepted the party's nomination on August 22.
The 403,000 strong People's Liberation Army Air Force (PLAAF) was organized into five Theatre Command Air Forces (TCAF) and 24 air divisions. As of 2024, the system has been changed into 11 Corps Deputy-grade "Bases" controlling air brigades. Divisions have been mostly converted to brigades, although some (specifically the Bomber divisions, and some of the special mission units) remain operational as divisions. The largest operational units within the Aviation Corps is the air division, which has 2 to 3 aviation regiments, each with 20 to 36 aircraft. An Air Brigade has from 24 to 50 aircraft. The surface-to-air missile (SAM) Corps is organized into SAM divisions and brigades. There are also three airborne divisions manned by the PLAAF. J-XX and XXJ are names applied by Western intelligence agencies to describe programs by the People's Republic of China to develop one or more fifth-generation fighter aircraft. The PLAAF is led by Commander Chang Dingqiu and Political Commissar Guo Puxiao.
The study of these structures and related self-organized systems is known as "chemobrionics", an emerging interdisciplinary field that integrates the concepts of physics, chemistry, materials science, biology and complex systems science to investigate reaction-diffusion-driven pattern formation. The term chemobrionics derives from "chemo" and the Greek word bruein ("to grow or enlarge"), referring to the osmotically driven growth of chemical gardens and related self-organized inorganic systems.
== Family == Pedersen was the son of the village schoolteacher Niels Christian Pedersen and Karen Marie (Ane) Pedersen and one of ten children; he was the elder brother of Thorvald Andreas Pedersen (1887–1961), with whom he co-founded Novo Terapeutisk Laboratorium. He married twice: he was widowed in 1916 when his first wife died in childbirth with their fifth child; a few years later he married Ane Thomine Thomsen, and they had a daughter, Gudrun. Gudrun married Knud Hallas-Møller, who later succeeded Harald in leading Novo; their daughter Lise married Mads Øvlisen, who later served as CEO of Novo Nordisk and helped bring about the 1989 merger of Novo and Nordisk.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.